LOGIN IN
REGISTER
PRODUCTS
More than 5000 active chemicals with high quality for research!

Email sales@dcchemicals.com

        order@dcchemicals.com

        info@dcchemicals.com


Phone:  +86-21-58447131

Fax   +86-21-61642470

SAGE-217
DC10802  (CAS:1632051-40-1)
(Based on popularity)
Size Price Availability
10mg USD 650 In stock
25mg USD 1000 In stock
100mg USD 1900 In stock
We match the best price and quality on market.
 
 
Email: order@dcchemicals.com
Tel: +86-21-58447131
Fax:+86-21-61642470
Fields of Application :
SAGE-217 is a potent GABAA receptor agonist with EC50s of 296 and 163 nM for 122 and 43 GABAA receptors, respectively.
CAS Number: 1632051-40-1
Purity:

>98%

Molecular Weight: 409.56
Molecular Formula: C25H35N3O2
Quality Control: HPLCNMR LC/MS(Please contact us to get the QC report)
Synonyms: SAGE-217; SAGE 217; SAGE217,1632051-40-1
Chemical Name: 1-(2-((3R,5R,8R,9R,10S,13S,14S,17S)-3-hydroxy-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl)-1H-pyrazole-4-carbonitrile
Storage: 2 years -20C Powder, 2 weeks4C in DMSO,6 months-80C in DMSO
Note: Products for research use only, not for human use
Description:
Kinase assay demonstrates that SAGE-217 is a potent GABAA receptor agonist with EC50s of 296 and 163 nM for 122 and 43 GABAA receptors, respectively. SAGE-217 is currently being studied in parallel phase 2 clinical trials for the treatment of postpartum depression (PPD) and major depressive disorder (MDD). SAGE-217 shows >30 M inhibition in a cardiac panel of eight relevant cardiac ion channels. At 10 M concentration of SAGE-217, only binding at the glycine (57%), sigma receptors (88%), and inhibition of the transient receptor potential vanilloid 1 (TRPV1, 95%) is noted.Acute administration of SAGE-217 (0.3 to 10 mg/kg, ip) effectively reduces pentylenetretazol (PTZ)-induced seizures in mice (MECplasma=85 nM) as well as produces a dose-dependent anticonvulsant effect in the mouse 6 Hz electrical stimulation model. In the rat lithium-pilocarpine model of status epilepticus (SE), SAGE-217 (0.3 to 5 mg, iv) abolishes both behavioral and electrographic seizure activity, even when administered 60 min after induction of SE. Additional PK studies of SAGE-217 in dog show low clearance (<10% of hepatic blood flow), resulting in excellent oral bioavailability (F=68%).
References:
O=C(CN1N=CC(C#N)=C1)[C@H]2CC[C@@]3([H])[C@]4([H])CC[C@]5([H])C[C@](C)(O)CC[C@]5([H])[C@@]4([H])CC[C@@]32C
About us Products Services ordering sitemap
Phone: +86-21-58447131Fax: +86-21-61642470
ADDRoom 610, Building 15, Jinxiang Rd 201, Pudong,Shanghai, China
CopyRight-2010-2013 DC Chemicals All Rights Reserved